Polyrizon Ltd. ( PLRZ ) shares are moving higher after the company announced it secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine.

The Details: Under the agreement, Eurofins will supply Polyrizon ( PLRZ ) with Clinical Trial Material (CTM) for its PL-14 allergy blocker trial.

The clinical trial, expected to commence in 2025, will evaluate the safety and efficacy of PL-14.

Tomer Izraeli, CEO of Polyrizon ( PLRZ ) previously stated that, “We are pleased to have established this partnership with Eurofins CDMO Amatsiaquitaine S.A.S, which strengthens our preparation efforts for the upcoming PL-14 clinical trial. We believe that this collaboration marks a significant milestone in our journey toward providing effective allergy protection solutions to patients.”

Polyrizon ( PLRZ ) stock is trading on higher-than-normal volume at 72.09 million. The company’s average session volume over the past 100 days is about 556.58 thousand.

See Also: What’s Going On With Quantum Computing (QUBT) Stock?

PLRZ Price Action: At the time of writing, Polyrizon ( PLRZ ) stock is trading 240.9% higher at $3.55, according to data from Benzinga Pro.

Image: Michal Jarmoluk from Pixabay